title: Implementation of NICE recommendation for a policy of routine antenatal anti-D prophylaxis: a survey of UK maternity units.
abstract: The aim of this study was to determine how many UK maternity units have implemented National Institute for Clinical Excellence (NICE) guidance for routine antenatal anti-D prophylaxis (RAADP). In May 2002, the NICE recommended a policy of RAADP for RhD-negative pregnant women. The policy has the potential to reduce maternal sensitization and prevent deaths from haemolytic disease of the foetus and newborn, but implementation entails considerable clinical, financial and organizational challenges. A postal survey of all 324 UK maternity units was completed in 2005.Responses were received from 91% of units (294 of 324). RAADP was offered by 220 of 294 (75%) and in England and Wales 19% of those offered a single-dose regime. At 12% of maternity units, routine paternal blood group testing was offered. For 84% of maternity units, staff education was offered at the time of implementation. Written patient information was provided at 97% of maternity units and 147 of 217 (69%) returned a copy. We received 60 different leaflets. Three years after NICE guidance was issued, one in four maternity units did not offer RAADP. Among those that do offer RAADP, practice with regard to anti-D administration, paternal testing, provision of written information and staff education varied. Unit and clinician level research is required to understand why.
authors.affiliation: Better Blood Transfusion Programme, Scottish National Blood Transfusion Service, Edinburgh, UK. mairi.harkness@snbts.csa.scot.nhs.uk
authors.forename: M
authors.initials: M
authors.lastname: Harkness
authors.forename: Y
authors.initials: Y
authors.lastname: Freer
authors.forename: R J
authors.initials: RJ
authors.lastname: Prescott
authors.forename: P
authors.initials: P
authors.lastname: Warner
mesh_terms: D000328:Adult; D016550:Birthing Centers / Q000706:statistics & numerical data*; D001788:Blood Grouping and Crossmatching / Q000592:standards / Q000706:statistics & numerical data*; D003696:Delivery Rooms / Q000706:statistics & numerical data*; D004899:Erythroblastosis, Fetal / Q000517:prevention & control*; D005260:Female; D005313:Fetal Death / Q000517:prevention & control; D019983:Guideline Adherence / Q000706:statistics & numerical data; D006282:Health Personnel / Q000193:education; D006801:Humans; D007231:Infant, Newborn; D007518:Isoantibodies / Q000008:administration & dosage*; D008297:Male; D010353:Patient Education as Topic; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D011295:Prenatal Care / Q000592:standards*; D012203:Rh Isoimmunization / Q000517:prevention & control*; D018029:Rho(D) Immune Globulin / Q000008:administration & dosage*; D011795:Surveys and Questionnaires; D006113:United Kingdom
chemical_list: D007518:Isoantibodies; C061961:RHO(D) antibody; D018029:Rho(D) Immune Globulin